Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the drug later this year.

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...

One such ADC is Patritumab Deruxtecan. Promising clinical activity is also seen when bispecific antibodies, like zenocutuzumab, target HER3 and HER2. Pharmaceutical companies actively pursue ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant disease. "The hypothesis is that tumors that have resistance to EGFR TKIs ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

“With the other arm, one can zoom in and block a molecule such as HER3 that is expressed at a considerably lower level,” said Logtenberg. “Such a ‘dock and block’ mechanism mediated by ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...